Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
116 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00196742 | Fabry Disease Registry & Pregnancy Sub-registry | recruiting | — | 9,000 | Genzyme, a Sanofi CompanyINDUSTRY | 44 | Jun 23, 2026 | clinicaltrials |
| NCT00410761 | An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer | completed | Phase 3 | 331 | Genzyme, a Sanofi CompanyINDUSTRY | 24 | Sep 24, 2025 | clinicaltrials |
| NCT00418886 |
| Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients(ZEAL) |
| completed |
| Phase 3 |
| 698 |
| Genzyme, a Sanofi CompanyINDUSTRY |
| 21 |
| Dec 31, 2024 |
| clinicaltrials |
| NCT01945762 | Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer(Caprelsa104) | completed | — | 31 | Genzyme, a Sanofi CompanyINDUSTRY | 8 | Dec 18, 2024 | clinicaltrials |
| NCT01876784 | Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer(VERIFY) | completed | Phase 3 | 238 | Genzyme, a Sanofi CompanyINDUSTRY | 12 | Jul 23, 2024 | clinicaltrials |
| NCT00537095 | Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer | completed | Phase 2 | 164 | Genzyme, a Sanofi CompanyINDUSTRY | 7 | Apr 19, 2024 | clinicaltrials |
| NCT00042341 | Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL) | completed | Phase 2 | 60 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | May 27, 2022 | clinicaltrials |
| NCT00531232 | A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS) | completed | Phase 2 | 38 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 24, 2022 | clinicaltrials |
| NCT00002348 | A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkin's Lymphoma | completed | Phase 2 | — | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT00003821 | Aminopterin in Treating Patients With Recurrent or Refractory Endometrial Cancer | withdrawn | Phase 2 | 0 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Sep 18, 2018 | clinicaltrials |
| NCT00005645 | ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment | withdrawn | Phase 2 | 0 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Sep 18, 2018 | clinicaltrials |
| NCT00003713 | Chemotherapy in Treating Patients With Advanced or Metastatic Solid Tumors | completed | Phase 1 | 35 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | Aug 29, 2018 | clinicaltrials |
| NCT00003822 | SR-45023A in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 30 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 29, 2018 | clinicaltrials |
| NCT00004049 | SR-45023A in Treating Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 36 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 29, 2018 | clinicaltrials |
| NCT00098345 | Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer | completed | Phase 2 | 40 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | May 7, 2018 | clinicaltrials |
| NCT00364351 | Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy | completed | Phase 3 | 1,574 | Genzyme, a Sanofi CompanyINDUSTRY | 22 | Jan 25, 2018 | clinicaltrials |
| NCT00500292 | A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer | completed | Phase 2 | 109 | Genzyme, a Sanofi CompanyINDUSTRY | 6 | Jan 25, 2018 | clinicaltrials |
| NCT01288573 | A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone | completed | Phase 1 / Phase 2 | 46 | Genzyme, a Sanofi CompanyINDUSTRY | 12 | May 16, 2017 | clinicaltrials |
| NCT02109250 | CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice(CaprelsaReg) | completed | — | 10 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | May 2, 2017 | clinicaltrials |
| NCT00358956 | A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer | completed | Phase 2 | 19 | Genzyme, a Sanofi CompanyINDUSTRY | 8 | Jan 30, 2017 | clinicaltrials |
| NCT00686036 | Trial Assessing Zactima Against Placebo in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy(ZENITH) | terminated | Phase 2 | 17 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 21, 2016 | clinicaltrials |
| NCT00659438 | Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer | completed | Phase 2 | 95 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 5, 2016 | clinicaltrials |
| NCT00752986 | ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial(ZACFAST) | terminated | Phase 2 | 39 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 5, 2016 | clinicaltrials |
| NCT01661179 | Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma | completed | Phase 1 / Phase 2 | 14 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 5, 2016 | clinicaltrials |
| NCT00753714 | Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus Gemcitabine(ZELIG) | completed | Phase 2 | 124 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Oct 17, 2016 | clinicaltrials |
| NCT00508001 | Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 67 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Oct 10, 2016 | clinicaltrials |
| NCT00597116 | An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma | terminated | Phase 2 | 25 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | Oct 10, 2016 | clinicaltrials |
| NCT00753675 | Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer(VANGOGH) | completed | Phase 2 | 174 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Oct 10, 2016 | clinicaltrials |
| NCT00777179 | Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy | completed | Phase 2 | 117 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Oct 10, 2016 | clinicaltrials |
| NCT00862836 | Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)(ZACFAST) | terminated | Phase 1 / Phase 2 | 15 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Oct 10, 2016 | clinicaltrials |
| NCT00454116 | A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients | completed | Phase 2 | 106 | Genzyme, a Sanofi CompanyINDUSTRY | 6 | Oct 7, 2016 | clinicaltrials |
| NCT00312377 | ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer(ZODIAC) | completed | Phase 3 | 1,690 | Genzyme, a Sanofi CompanyINDUSTRY | 25 | Sep 30, 2016 | clinicaltrials |
| NCT00404924 | ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures | completed | Phase 3 | 1,140 | Genzyme, a Sanofi CompanyINDUSTRY | 22 | Sep 30, 2016 | clinicaltrials |
| NCT00494481 | E3 Breast Cancer Taxotere Combination | completed | Phase 2 | 64 | Genzyme, a Sanofi CompanyINDUSTRY | 5 | Sep 30, 2016 | clinicaltrials |
| NCT00503711 | Phase I Chinese PK | completed | Phase 1 | 36 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 31, 2016 | clinicaltrials |
| NCT01757470 | Vandetanib Risk Minimisation Effectiveness | completed | — | 12 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 31, 2016 | clinicaltrials |
| NCT00206726 | Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)(ECO-1) | completed | Phase 2 | 60 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 29, 2016 | clinicaltrials |
| NCT00496275 | Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLC | completed | Phase 1 | 17 | Genzyme, a Sanofi CompanyINDUSTRY | 0 | Aug 26, 2016 | clinicaltrials |
| NCT00496509 | Phase I Efficacy On Vascular Permeability In Patients With Advanced Colorectal Cancer | completed | Phase 1 | 24 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 26, 2016 | clinicaltrials |
| NCT00047840 | This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer. | completed | Phase 2 | 129 | Genzyme, a Sanofi CompanyINDUSTRY | 3 | Aug 25, 2016 | clinicaltrials |
| NCT00071188 | ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | — | Genzyme, a Sanofi CompanyINDUSTRY | 9 | Aug 25, 2016 | clinicaltrials |
| NCT00252746 | ZD6474 Phase IIa Dose Finding Multicentre Study | completed | Phase 2 | 53 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 25, 2016 | clinicaltrials |
| NCT00499850 | Phase I FOLFOX Combination | completed | Phase 1 | 18 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 25, 2016 | clinicaltrials |
| NCT00506051 | ZD6474(Vandetanib) + Alimta Combo Study | completed | Phase 1 | 21 | Genzyme, a Sanofi CompanyINDUSTRY | 0 | Aug 25, 2016 | clinicaltrials |
| NCT00507091 | Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination | completed | Phase 1 | 24 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | Aug 25, 2016 | clinicaltrials |
| NCT00034918 | This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer | completed | Phase 2 | 44 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | Aug 24, 2016 | clinicaltrials |
| NCT00047788 | Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer | completed | Phase 2 | 30 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | Aug 24, 2016 | clinicaltrials |
| NCT00059722 | This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC. | completed | Phase 2 | 160 | Genzyme, a Sanofi CompanyINDUSTRY | 6 | Aug 24, 2016 | clinicaltrials |
| NCT00066313 | ZD6474 in Treating Patients With Small Cell Lung Cancer | completed | Phase 2 | — | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 24, 2016 | clinicaltrials |
| NCT01362972 | Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry on a Cohort of Patients Receiving Plerixafor | completed | — | 7,801 | Genzyme, a Sanofi CompanyINDUSTRY | 0 | Aug 24, 2016 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials